Posts Positive Organic Growth and Adjusted EBITDA1 of 23.5% of Revenue CINCINNATI, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Quipt Home…
SHANGHAI, July 16, 2025 /PRNewswire/ -- In the newly released "Paediatric drug optimization for respiratory syncytial virus (PADO-RSV) meeting report"…
Dräger recognized for pioneering innovations in respiratory care, delivering measurable improvements in patient outcomes, clinical efficiency, cost-effectiveness and critical care…
EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever…